Edmund Ingham is an Investing Group Leader at Haggerston BioHealth. With over 5 years of experience covering biotech, healthcare, and pharma, he specializes in themes such as psychedelic research, investment strategies, and healthcare technology. His insights and analyses have been featured in Seeking Alpha.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
United States (National)
Not enough data
Edmund Ingham's articles predominantly focus on investment analysis, particularly in the finance and healthcare & pharmaceutical sectors. Given this, he is likely to be most responsive to pitches that offer expert insights into stock performance, company earnings reports, or detailed financial analysis within these industries.
Considering his extensive use of data and statistics in his coverage attributes, Edmund would likely appreciate pitches from sources who can provide credible quantitative analysis related to stock performances or trends within the pharmaceutical and biotech sectors.
While no specific geographic focus is mentioned for Edmund’s articles, it seems that he covers global companies listed on major exchanges like NYSE. Therefore, pitching international perspectives backed by relevant data could be beneficial when reaching out to him.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Edmund Ingham
Summary BioCryst Pharmaceuticals, Inc. is upgraded to Buy, reflecting strong execution in HAE and a compelling pipeline with Orladeyo and navenibart.
By: Edmund Ingham
Summary Eli Lilly and Company has become the world's most valuable pharma, driven by dominant T2D/obesity franchises and a >400% five-year stock price surge.
By: Edmund Ingham
Summary uniQure N.V. surges as the FDA now accepts Phase 1/2 data for AMT-130 as the primary basis for accelerated approval in Huntington's disease.
By: Edmund Ingham
Summary Sarepta Therapeutics, Inc. faces a challenging outlook, with 2025 marked by safety setbacks, missed endpoints, and a sharp share price decline.
By: Edmund Ingham
The FDA approves Utebzi, boosting Spero Therapeutics, Inc. via GSK milestones and royalties. Click for more on SPRO stock and see if it is right for you.
By: Edmund Ingham
Summary Relmada Therapeutics maintains a hold rating as NDV-01 advances, with recent 12-month Phase 2 data showing strong complete response rates in NMIBC.
By: Edmund Ingham
Teladoc Health, Inc. upgraded to Hold as strategy shifts and new growth tests emerge. Click for this updated look at TDOC stock and see if it is right for you.
By: Edmund Ingham
AbbVie Inc.’s $10.9B Apogee Therapeutics, Inc. buyout boosts its immunology pipeline with APG777 for atopic dermatitis. Click for this ABBV stock update.
By: Edmund Ingham
Definium Therapeutics surged ~50% after positive Phase 3 EMERGE data for DT120 in major depressive disorder, demonstrating rapid, robust, and durable efficacy.
Summary Absci Corporation stock surged over 30% after announcing a $100M equity offering with Eli Lilly as a key participant.
